Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and tolerability

References

• Santen UK. Taptiqom 15 micrograms/ml + 5 mg/ml eye drops, solution in single-dose container Summary of product characteristics . 2021. [cited 2021 Feb 15]. Available from: https://medicines.org.uk/emc/product/6917
   Google Scholar
• European Glaucoma Society. Terminology and guidelines for glaucoma. 2020 cited 2022 Aug 15]. Available from 2022 Aug 15: https://eugs.org/eng/egs_guidelines_reg.asp?l=1.
   Google Scholar
• International Council of Ophthalmology. Guidelines for glaucoma care. 2016 cited 2022 Aug 15]. Available from 2022 Aug 15: https://icoph.org/eye-care-delivery/glaucoma/.
   Google Scholar
• Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17(17):341–349.
   PubMedGoogle Scholar
• Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86(7):716–726.
   PubMed Web of Science ®Google Scholar
• Kaštelan S, Tomić M, Metež Soldo K, et al. How ocular surface disease impacts the glaucoma treatment outcome. Biomed Res Int. 2013;2013:696328.
   PubMed Web of Science ®Google Scholar
• Asiedu K, Abu SL. The impact of topical intraocular pressure lowering medications on the ocular surface of glaucoma patients: a review. J Curr Ophthalmol. 2019;31(1):8–15.
   PubMed Web of Science ®Google Scholar
• Aguayo Bonniard A, Yeung JY, Chan CC, et al. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016;12(11):1279–1289.
   PubMed Web of Science ®Google Scholar
• Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye Graefe’s archive for clinical and experimental ophthalmology [German].J Glaucoma 2008;246(11):1593–1601.
   Google Scholar
• Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22(9):730–735.
   PubMed Web of Science ®Google Scholar
• Aptel F, Denis P. Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma. Curr Med Res Opin. 2011;27(10):1949–1958.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418–423.
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355.
   PubMed Web of Science ®Google Scholar
• Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol. 2012;6:441–446.
   PubMedGoogle Scholar
• Mylla Boso AL, Gasperi E, Fernandes L, et al. Impact of ocular surface disease treatment in patients with glaucoma. Clin Ophthalmol. 2020;14:103–111.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Riva I, Gerardi C, et al. Quality of life in glaucoma: a review of the literature. Adv Ther. 2016;33(6):959–981.
   PubMed Web of Science ®Google Scholar
• Kaarniranta K, Ikäheimo K, Mannermaa E, et al. Pharmacokinetics, efficacy, and safety of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in healthy volunteers: a Phase I comparison vs. the corresponding preservative-free monotherapies. Clin Pharmacokinet. 2016;55(4):485–494.
   PubMed Web of Science ®Google Scholar
• Pfeiffer N, Traverso CE, Lorenz K, et al., A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. Adv Ther. 2014;31(31): 1228–1246.
   PubMedGoogle Scholar
• Holló G, Hommer A, Antón López A, et al., Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients. J Ocul Pharmacol Ther. 2014;30(6): 468–475.
   PubMed Web of Science ®Google Scholar
• Pillunat LE, Erb C, Ropo A, et al. Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study. Clin Ophthalmol. 2017;11:1051–1064.
   PubMed Web of Science ®Google Scholar
• Bourne RRA, Kaarniranta K, Lorenz K, et al., Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study. BMJ Open. 2019;9(4): e024129.
   PubMed Web of Science ®Google Scholar
• Oddone F, Tanga L, Kóthy P, et al., Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: the VISIONARY study. Adv Ther.2020; 37(37): 1436–1451.
   PubMedGoogle Scholar
• Garcia-Medina JJ, Benitez-Del-Castillo J, Rodríguez-Agirretxe I, et al. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: results from the VISIONARY study population in Spain. J Ocul Pharmacol Ther. 2022;38(3):252–260.
   PubMed Web of Science ®Google Scholar
• Ansari E, Pavicic-Astalos J, Ayan F, et al. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: UK and Ireland results from the VISIONARY study. Adv Ther. 2021;38(38):2990–3002.
   PubMedGoogle Scholar
• v KE, Petrov SY, Germanova VN. Preservative-free fixed combination in the treatment of open-angle glaucoma and ocular hypertension: the VISIONARY Study (EUPAS22204) [Russian]. Vestn Oftalmol. 2020;136(4):76–84.
   PubMedGoogle Scholar
• Holló G, Kóthy P. A magyarországi VISIONARY vizsgálók. The Hungarian VISIONARY Study: Hungarian results in the European multicenter preservative-free tafluprost/timolol fixed combination investigation [Hungarian]. Ophth Hungarica. 2020;57:196–201.
   Google Scholar
• Konstas AGP, Quaranta L, Bozkurt B, et al. 24-h efficacy of glaucoma treatment options. Adv Ther. 2016;33(4):481–517.
   PubMed Web of Science ®Google Scholar
• Holló G, Katsanos A. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. Expert Opin Drug Saf. 2015;14(4):609–617.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Tafluprost/Timolol: a review in open-angle glaucoma or ocular hypertension. Drugs. 2015;75(15):1807–1813.
   PubMed Web of Science ®Google Scholar
• Holló G, Vuorinen J, Tuominen J, et al., Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014;31(9): 932–944.
   PubMed Web of Science ®Google Scholar
• Oddone F, Kirwan J, Lopez-Lopez F, et al., Switching to preservative-free tafluprost/timolol fixed-dose combination in the treatment of open-angle glaucoma or ocular hypertension: subanalysis of data from the VISIONARY study according to baseline monotherapy treatment. Adv Ther.2022; 39(8): 3501–3521.
   PubMed Web of Science ®Google Scholar
• Negri L, Ferreras A, Iester M. Timolol 0.1% in glaucomatous patients: efficacy, tolerance, and quality of life. J Ophthalmol. 2019;2019:4146124.
   PubMed Web of Science ®Google Scholar
• Lazreg S, Merad Z, Nouri MT, et al. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naive patients and patients intolerant to other hypotensive medications. J Fr Ophtalmol. 2018;41(41):945–954.
   PubMedGoogle Scholar
• Mäenpää J, Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016;15(11):1549–1561.
   PubMed Web of Science ®Google Scholar
• Radcliffe NM. The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clin Ophthalmol. 2014;8:2541–2549.
   PubMedGoogle Scholar
• Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clin Ophthalmol. 2013;7(7):2131–2135.
   PubMedGoogle Scholar
• Rolle T, Curto D, Alovisi C, et al. Timogel® vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance. Eur J Ophthalmol. 2012;22(22):28–33.
   PubMedGoogle Scholar
• Lee PW-Y, Doyle A, Stewart JA, et al. Meta-analysis of timolol on diurnal and nighttime intraocular pressure and blood pressure. Eur J Ophthalmol. 2010;20(20):1035–1041.
   PubMedGoogle Scholar
• Kass MA. Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: a five-year, randomized, double-masked, clinical trial. Trans Am Ophthalmol Soc. 1989;87:598–618.
   PubMedGoogle Scholar
• Dunn FG, Frohlich ED. Pharmacokinetics, mechanisms of action, indications, and adverse effects of timolol maleate, a nonselective beta-adrenoreceptor blocking agent. Pharmacotherapy. 1981;1(3):188–200.
   PubMed Web of Science ®Google Scholar
• Boger WP, Puliafito CA, Steinert RF, et al. Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology. 1978;85(3):259–267.
   PubMed Web of Science ®Google Scholar
• Ritch R, Hargett NA, Podos SM. The effect of 1.5% timolol maleate on intraocular pressure. Acta Ophthalmol. 1978;56(1):6–10.
   Web of Science ®Google Scholar
• Zimmerman TJ, Kaufman HE. Timolol, dose response and duration of action. Arch Ophthalmol. 1977;95(4):605–607.
   PubMedGoogle Scholar
• Zimmerman TJ, Kaufman HE. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95(4):601–604.
   PubMedGoogle Scholar
• Chabi A, Baranak C, Lupinacci R, et al. Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial. Int J Clin Pract. 2016;70(7):577–586.
   PubMed Web of Science ®Google Scholar
• Ruangvaravate N, Choojun K, Srikulsasitorn B, et al. Ocular surface changes after switching from other prostaglandins to tafluprost and preservative-free tafluprost in glaucoma patients. Clin Ophthalmol. 2020;14:3109–3119.
   PubMed Web of Science ®Google Scholar
• Tumbocon JA, Macasaet AM. Efficacy and safety of tafluprost 0.0015% – retrospective analysis of real-world data from the Philippines. Clin Ophthalmol. 2019;13:1627–1634.
   PubMed Web of Science ®Google Scholar
• El Hajj Moussa Wg, Farhat RG, Nehme JC, et al. Comparison of efficacy and ocular surface disease index score between bimatoprost, latanoprost, travoprost, and tafluprost in glaucoma patients. J Ophthalmol. 2018;2018:1319628.
   PubMed Web of Science ®Google Scholar
• Rolle T, Spinetta R, Nuzzi R. Long term safety and tolerability of tafluprost 0.0015% vs timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study. BMC Ophthalmol. 2017;17(1):136.
   PubMedGoogle Scholar
• Kuwayama Y, Hashimoto M, Kakegawa R, et al. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: effectiveness and treatment persistence. Adv Ther. 2017;34(6):1411–1425.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Egorov E, Kaarniranta K, et al. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clin Ophthalmol. 2016;10:445–454.
   PubMed Web of Science ®Google Scholar
• Fogagnolo P, Dipinto A, Vanzulli E, et al. A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients. Adv Ther. 2015;32(4):356–369.
   PubMed Web of Science ®Google Scholar
• Weindler H, Spitzer MS, Schultheiß M, et al. OCT angiography analysis of retinal vessel density in primary open-angle glaucoma with and without Tafluprost therapy. BMC Ophthalmol. 2020;20(1):444.
   PubMed Web of Science ®Google Scholar
• Iida Y, Akagi T, Nakanishi H, et al. Retinal blood flow velocity change in parafoveal capillary after topical tafluprost treatment in eyes with primary open-angle glaucoma. Sci Rep. 2017;7(1):5019.
   PubMedGoogle Scholar
• Schultz C. Tafluprost for the reduction of interocular pressure in open angle glaucoma and ocular hypertension. Ophthalmol Eye Dis. 2011;3:13–19.
   PubMedGoogle Scholar
• Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30(2–3):102–109.
   PubMed Web of Science ®Google Scholar
• Kim JM, Park SW, Seong M, et al. Comparison of the safety and efficacy between preserved and preservative-free latanoprost and preservative-free tafluprost. Pharmaceuticals (Basel). 2021;14(6):501.
   PubMedGoogle Scholar
• Tapply I, Broadway DC. Improving adherence to topical medication in patients with glaucoma. Patient Prefer Adherence. 2021;15:1477–1489.
   PubMed Web of Science ®Google Scholar
• Abbas SA, Hamadani SM, Ahmad U, et al. Ophthalmic timolol and hospitalization for symptomatic bradycardia and syncope: a case series. Cureus. 2020;12(3):e7270.
   PubMed Web of Science ®Google Scholar
• Wang Z, Denys I, Chen F, et al. Complete atrioventricular block due to timolol eye drops: a case report and literature review. BMC Pharmacol Toxicol. 2019;20(1):73.
   PubMed Web of Science ®Google Scholar
• Ansari E, Chappiti S, Pavicic-Astalos J, et al., Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: 6 case reports and clinical outcomes. BMC Ophthalmol. 2022;22(1): 152.
   PubMed Web of Science ®Google Scholar
• Dubrulle P, Labbé A, Brasnu E, et al. Influence of treating ocular surface disease on intraocular pressure in glaucoma patients intolerant to their topical treatments: a report of 10 cases. J Glaucoma. 2018;27(12):1105–1111.
   PubMed Web of Science ®Google Scholar